number of ozempic wegovy prescriptions q3 2024 semaglutide tirzepatide shortage ends as FDA sets deadline for compounders How to Invest in GLP-1

Most people experience the worst nausea within the first 24 weeks after starting therapy or increasing their dose

In the SURMOUNT-1 trial, participants without diabetes lost an average of 15-22% of their body weight over 72 weeks, depending on the dose (5-15mg)

The study was stopped early because the results were so clearly positive

Patients seeking detoxification often find glutathione IV therapy to be a powerful ally, enabling them to enhance their liver health while also promoting overall well-being

To date, the latter includes the GLP-1 RAs liraglutide and semaglutide, and the SGLT2 inhibitors empagliflozin and canagliflozin